Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before–after Analysis

Fluvoxamine, a selective serotonin reuptake inhibitor with anti-inflammatory properties, has gained attention as a repurposed drug to treat COVID-19. We aimed to explore the potential benefit of fluvoxamine on outpatients with early SARS-CoV-2 infection. We performed a retrospective study of fluvoxa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsiakalos, Aristotelis, Ziakas, Panayiotis D., Polyzou, Eleni, Schinas, Georgios, Akinosoglou, Karolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459506/
https://www.ncbi.nlm.nih.gov/pubmed/37630633
http://dx.doi.org/10.3390/microorganisms11082073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459506/
https://www.ncbi.nlm.nih.gov/pubmed/37630633
http://dx.doi.org/10.3390/microorganisms11082073

Ejemplares similares